Trials / Active Not Recruiting
Active Not RecruitingNCT04586660
Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XGEVA® | Participants will receive XGEVA® 120 mg subcutaneously (SC) once every 4 weeks (Q4W) with a loading dose of 120 mg SC on day 8 and day 15. |
Timeline
- Start date
- 2023-08-17
- Primary completion
- 2028-03-07
- Completion
- 2028-03-07
- First posted
- 2020-10-14
- Last updated
- 2025-10-01
Locations
10 sites across 2 countries: China, Taiwan
Source: ClinicalTrials.gov record NCT04586660. Inclusion in this directory is not an endorsement.